BIND Therapeutics Initial Public Offering
Davis Polk advised Credit Suisse Securities (USA) LLC and Cowen and Company, LLC as joint book-running managers in connection with the $70.5 million initial public offering of common stock by BIND Therapeutics, Inc. BIND’s common stock is listed on the Nasdaq Global Select Market under the symbol "BIND."
Based in Cambridge, Massachusetts, BIND Therapeutics is a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurin.